目的 对546株常见病原菌进行耐药分析，为感染性疾病的临床治疗提供依据。 方法 对2012年4月－9月从临床标本中分离的546株常见病原菌进行耐药分析，菌种鉴定及药物敏感试验结果由法国生物梅里埃公司VITEK 2 COMPACT系统完成。 结果 在546株病原菌中，G−杆菌占82.8%，其前3位分别为大肠埃希菌（占22.2%），鲍曼/溶血不动杆菌（占16.5%），肺炎克雷伯菌（占15.4%）。在G−杆菌中，除嗜麦芽窄食单孢菌外，亚胺培南、厄它培南的耐药率最低，其次为丁胺卡那霉素和哌拉西林/他唑巴坦。鲍曼/溶血不动杆菌、肺炎克雷伯菌、铜绿假单孢对氨苄青霉素的耐药率均超过95%。金黄色葡萄球菌的耐药率较凝固酶阴性葡萄球菌低，耐甲氧西林金黄色葡萄球菌占22.00%；而耐甲氧西林凝固酶阴性葡萄球菌占94.44%。此外，金黄色葡萄球菌和凝固酶阴性葡萄球菌对万古霉素、利奈唑胺、替加环素、奎奴普丁/达福普丁、呋喃妥因的耐药率为0.00%。 结论 在该院新院区临床标本分离的常见病原菌中，仍以G−杆菌占优势。在G−杆菌中，除嗜麦芽窄食单孢菌外，亚胺培南、厄它培南的耐药率最低。金黄色葡萄球菌的耐药率较凝固酶阴性葡萄球菌低，且尚未发现对万古霉素耐药的葡萄球菌。
目的：对鲍曼不动杆菌感染的临床特征和耐药性进行分析，为临床诊治提供参考。方法：对2005年1月～2006年6月我院临床分离的共107株鲍曼不动杆菌通过琼脂对倍稀释法进行MIC测定；同时对相应的临床病例进行回顾性分析。结果：107株鲍曼不动杆菌大多分离自痰液，主要来自于ICU病房；且91.59%的患者同时存在2种以上基础疾病。鲍曼不动杆菌对氨曲南耐药率最高，为89.72%，依次是头孢西丁(87.85%)，头孢哌酮(76.64%)、哌拉西林(69.16%)、头孢噻肟(65.42%)、环丙沙星(65.42%)、阿米卡星(56.07%)、头孢他定(5514%)等。结论：我院鲍曼不动杆菌耐药情况严重，治疗首选碳青霉烯类抗生素，其次可选用头孢吡肟、头孢哌酮/舒巴坦。
ObjectiveTo understand the drug resistance of Mycobacterium tuberculosis complex in West China Hospital, Sichuan University, analyze its drug resistance characteristics, and provide reference for the monitoring of drug-resistant tuberculosis.MethodsFrom January 2016 to March 2018, Mycobacterium tuberculosis drug susceptibility testing kit was used to detect the drug susceptibility of Mycobacterium tuberculosis culture-positive strains in Department of Laboratory Medicine, West China Hospital, Sichuan University. The tested drugs included four of the first-line anti-tuberculosis drugs: rifampicin, isoniazid, ethambutol, and streptomycin, and ten of the second-line anti-tuberculosis drugs: capreomycin, ofloxacin, ethionamide, p-aminosalicylic acid, levofloxacin, moxifloxacin, rifabutin, amikacin, kanamycin, and chlorine phenazine.ResultsA total of 130 patients (130 strains) were enrolled, including 82 newly diagnosed patients (82 strains) and 48 re-treated patients (42 strains). The drug resistance rate of the 130 patients was 37.69%. The drug resistance rate of the newly diagnosed patients (28.05%) was significantly lower than that of the re-treated patients (54.17%), and there was a statistical difference (χ2=8.794, P=0.003). The multi-drug resistance rate of the newly diagnosed patients (6.10%) was significantly lower than that of the re-treated patients (25.00%), and the difference was statistically significant (χ2=9.517, P=0.002). The resistance rate of isoniazid, rifampicin, and streptomycin in newly diagnosed patients (23.17%, 8.54%, and 7.32%, respectively) were significantly lower than those in the re-treated patients (45.83%, 41.67%, and 29.17%, respectively), and the differences were statistically significant (P<0.05). The resistance rate of ofloxacin, moxifloxacin, rifabutin and ethionamide in the newly diagnosed patients (9.76%, 8.54%, 7.31%, and 4.88%, respectively) were significantly lower than those in the re-treated patients (39.58%, 27.08%, 25.00%, and 22.92%, respectively), and the differences were statistically significant (P<0.05).ConclusionIt is necessary to strengthen the standardized treatment of patients with newly diagnosed tuberculosis, increase the treatment and management of re-treated tuberculosis patients, and prevent the generation and spread of drug-resistant patients, especially multidrug-resistant patients.
ObjectiveTo compare the clinical characteristics of patients with nosocomial and community infections with extended-spectrum beta-lactamase-containing Klebsiella pneumoniae (ESBL-KP) and non-ESBL-KP so as to improve clinical diagnosis and treatment outcomes.MethodsThis retrospective study determined the clinical features of patients with nosocomial and community infections with KP who were admitted to our hospital from January 1st, 2017 to June 30th, 2018. The chi-square test or Fisher's exact probability method were used to compare different groups.ResultsWe identified 334 strains of KP, and 83 (24.9%) of them strains were EBSL-KP. The percentages of ESBL-KP infections among those with nosocomial and community infections were similar (31.25% vs. 22.27%, χ2=2.955, P=0.086). Significantly more females than males had ESBL-KP infections (32.32 vs. 21.70%, χ2=4.208, P=0.040). The percentages of ESBL-KP infections were similar among <18 years-old group, 18 to 45 years-old group, 45 to 60 years-old group, and ≥60 years-old group. The three major locations of KP infections were the lower respiratory tract, urinary tract, and bloodstream (bacteremia). Among nosocomial KP infections, there were no significant differences in the percentages of ESBL-KP infections at different sites, nor in the hospital departments where patients were treated; among community KP infections, there were significant differences in the percentages of ESBLs-KP infections at different sites, and in the hospital departments where patients were treated. For community KP infections, the two most common infection sites were the urinary tract (37.74%) and the skin and soft tissue (30.77%), and most patients were treated in the urology department (40.00%) and respiratory medicine department (38.10%). ESBL-KP isolates had greater resistance than non-EBSL-KP isolates to 16 tested antibiotics (P<0.05). There were no statistically significant differences in the percentages of nosocomial infections and community infections among those with ESBL-KP and among those with non-ESBL-KP (P>0.05).ConclusionsOur population have high rates of nosocomial and community KP infections and of infections with ESBL-KP. It is necessary to strengthen the management and clinical use of antibiotics and to provide real-time surveillance of KP infections, especially for patients with ESBL-KP infections. Increased vigilance is required for KP infections of females and community KP infections to improve control of nosocomial infections and reduce the prevalence of cross-infections.